ACCELERATED DISCOVERY AND DEVELOPMENTS WITH MACHINE LEARNING
Our proprietary platform leverages graph knowledge technology and machine learning to help our customers discover and design new genomic therapies.
Based on exhaustive datasets, the platform provides in-silico simulations to discover and design optimized payloads and vectors.
OPTIMIZED STRATEGIES AND DECISIONS FOR YOUR BIOTHERAPIES
Thanks to our advanced software solutions and proprietary database, scientists in the field of genomic medicine are able to obtain precise and exhaustive answers to key scientific and technological questions such as optimizing payload and vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies.
Gene therapy is a revolutionary treatment designed to introduce a functional copy of a gene into cells in place of missing or defective ones in order to correct genetic disorders. Therapeutic effect can be achieved through insertion, deletion, inactivation, or modification of genetic sequences.
RNA therapeutics are a new class of medications based on ribonucleic acid (RNA). These drugs can either trigger protein synthesis to promote a new therapeutics effect, such as a vaccine, or they can activate an interfering mechanism in order to suppress pathological protein pathway expression and block the disease.
Cell therapy is a therapy in which viable cells are injected or implanted into a patient to trigger a medicinal effect. These cells are originally collated from a patient, cultured and transformed in vitro with therapeutic genetic material. The transformed cells which have the capability to cure the symptoms are re-injected in the patient.
By bringing together the power of computer sciences and biology, we help our customers develop more genomic medicines, faster, in leaner ways and make those revolutionary drugs more accessible to patients in need.
THE SPECIALIZED AI PLATFORM FOR DNA AND RNA THERAPIES.
… is how much some biotherapies can cost. Our technology enables scientists to reduce the development time of those therapies, enabling a faster access to market and cheaper therapeutic solutions available to more patients in needs.